Answers are grounded in this paper and cite their sources.
Mice lacking the enzyme fumarylacetoacetate hydrolase (FAH) have symptoms similar to humans with the disease hereditary tyrosinemia type I (HT1). FAH-deficient mice were injected with a first-generation adenoviral vector expressing the human FAH gene and followed for up to 9 months. Nontreated FAH mutant control mice died within 6 weeks from fulminant liver failure, whereas FAH adenovirus-infected animals survived until sacrifice at 2–9 months. Nine of 13 virus-treated animals developed hepatocellular cancer. Immunohistochemical analysis revealed a mosaic of FAH-deficient and FAH-positive cells in all animals and liver function tests were improved compared to controls. Even mice harvested 9 months after viral infection had >50% FAH-positive cells. These results demonstrate the strong selective advantage of FAH-expressing cells in an FAH-deficient liver but also illustrate the danger of carcinomas arising from FAH-deficient hepatocytes in HT1. In this study, we tested the effectiveness of a fumarylacetoacetate hydrolase (FAH)-expressing adenovirus in the treatment of a mouse model of the human disease hereditary tyrosinemia type I (HT1). Thirteen mice were treated with the recombinant adenovirus and analyzed at intervals ranging from 2 to 9 months after injection. All treated mice had improved survival, weight gain, and liver function tests. A high percentage (>20%) of hepatic cells remained FAH-positive, even 6–9 months post injection. However, 9 of 13 mice developed either microscopic or macroscopic hepatocellular carcinomas originating from nontransduced FAH-negative cells. This report demonstrates that adenoviral gene therapy of HT1 is aided by the strong selective advantage of FAH-expressing cells, but also that adenoviral gene therapy does not obviate the tumor risk inherent in HT1.
No takes yet. Share an insight, caveat, or question.
Overturf et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: